-
-
-
-
-
-
-
Guggenheim Starts Bicara Therapeutics Inc (BCAX) at Buy
-
-
-
-
-
-
-
Goldman Sachs Downgrades Bicara Therapeutics Inc (BCAX) to Neutral
-
-
-
-
-
-
-
Mizuho Starts Bicara Therapeutics Inc (BCAX) at Neutral
-
-
-
-
-
-
-
TD Cowen: 'Bicara Therapeutics Inc (BCAX) Remains An Attractive Investment'
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Bicara Therapeutics Inc (BCAX)
-
-
-
-
-
-
-
Bicara Therapeutics (BCAX) present updated data for Ficerafusp alfa in 1L trial
-
-
-
-
-
-
-
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01
-
416,810 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

